The Lynx Group

Colon Cancer

Chicago, IL—The global International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study suggests that some patients with surgically resected stage III colon cancer can safely and effectively receive only 3 months of chemotherapy instead of the standard 6 months. The data were particularly convincing for patients with low-risk, surgically resected stage III colon cancer. These data set a new standard for the treatment of patients with stage III colon cancer, according to expert opinion presented at the 2017 ASCO annual meeting.
Read Article

Left- vs Right-Sided Colon Cancers

Some molecularly targeted agents are proving to be less effective, not more so, when administered earlier in the disease course. Researchers say this is counterintuitive, because advanced disease is associated with treatment refractoriness, and cancer agents will typically perform better in the adjuvant treatment setting than in the metastatic treatment setting.
Read Article



Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: